chr13-57632849-G-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_001040429.3(PCDH17):āc.303G>Cā(p.Lys101Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000105 in 1,613,986 control chromosomes in the GnomAD database, with no homozygous occurrence. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: š 0.000020 ( 0 hom., cov: 32)
Exomes š: 0.0000096 ( 0 hom. )
Consequence
PCDH17
NM_001040429.3 missense
NM_001040429.3 missense
Scores
1
7
11
Clinical Significance
Conservation
PhyloP100: 5.08
Genes affected
PCDH17 (HGNC:14267): (protocadherin 17) This gene belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. The encoded protein contains six extracellular cadherin domains, a transmembrane domain, and a cytoplasmic tail differing from those of the classical cadherins. The encoded protein may play a role in the establishment and function of specific cell-cell connections in the brain. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAdExome4 at 14 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCDH17 | NM_001040429.3 | c.303G>C | p.Lys101Asn | missense_variant | 1/4 | ENST00000377918.8 | NP_001035519.1 | |
PCDH17 | XM_005266357.3 | c.303G>C | p.Lys101Asn | missense_variant | 2/5 | XP_005266414.1 | ||
PCDH17 | XM_047430276.1 | c.303G>C | p.Lys101Asn | missense_variant | 2/5 | XP_047286232.1 | ||
PCDH17 | XM_017020547.2 | c.303G>C | p.Lys101Asn | missense_variant | 1/4 | XP_016876036.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDH17 | ENST00000377918.8 | c.303G>C | p.Lys101Asn | missense_variant | 1/4 | 1 | NM_001040429.3 | ENSP00000367151.3 | ||
PCDH17 | ENST00000484979.5 | n.303G>C | non_coding_transcript_exon_variant | 1/4 | 1 | ENSP00000432899.1 | ||||
ENSG00000278722 | ENST00000610846.1 | n.564C>G | non_coding_transcript_exon_variant | 2/2 | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152156Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152156
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250868Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135682
GnomAD3 exomes
AF:
AC:
3
AN:
250868
Hom.:
AF XY:
AC XY:
1
AN XY:
135682
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461712Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727162
GnomAD4 exome
AF:
AC:
14
AN:
1461712
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
727162
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152274Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74444
GnomAD4 genome
AF:
AC:
3
AN:
152274
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74444
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
Asia WGS
AF:
AC:
4
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 14, 2024 | The c.303G>C (p.K101N) alteration is located in exon 1 (coding exon 1) of the PCDH17 gene. This alteration results from a G to C substitution at nucleotide position 303, causing the lysine (K) at amino acid position 101 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Uncertain
T
MetaSVM
Benign
T
MutationAssessor
Benign
L
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
T
Sift4G
Benign
T
Polyphen
D
Vest4
MutPred
Gain of catalytic residue at N99 (P = 0.001);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at